Catching Up With Fate: Deal With CRISPR Brings Nkarta Up In NK Cell Race

Partnership Seen As Validating CD70 As Antigen Target

 
• By Alaric DeArment

The partnership helps close the gap between Nkarta and Fate Therapeutics in terms of the breadth of their pipelines.

3D illustration of T cells attacking a cancer cell (CAR-T cell therapy) - Illustration
The deal between Nkarta and CRISPR includes CD70 plus an undetermined target • Source: Shutterstock

More from Deals

More from Business